title: [Dependence of the pharmacokinetics of captopril on the type of adaptation reactions in the organism].
abstract: The dependence of the pharmacokinetic profiles (PhP) of captopril in the phase of adaptation reactions in the organism has been studied within the framework of randomized, comparative, double cross research of bioeqivalency of captopril (Aspharma Co, Anzhero-Sudzhensk) and capoten (Bristol Myers Squibb Co.; official Russian producer, Akrikhin KhimFarmKombinat). It is established that the maximum bioaccessibility and high concentration of captopril in the blood plasma is determined on the background of physiologically optimum reactions of training and in the zone of quiet activation. These characteristics decrease during the reactions of general adaptation syndrome according to the type of increased activation and reactivation.
authors.forename: V V
authors.initials: VV
authors.lastname: Udut
authors.forename: V A
authors.initials: VA
authors.lastname: Khazanov
authors.forename: R V
authors.initials: RV
authors.lastname: Gurto
authors.forename: E V
authors.initials: EV
authors.lastname: Borodulina
authors.forename: Iu E
authors.initials: IuE
authors.lastname: Postnikova
mesh_terms: D000222:Adaptation, Physiological; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000493:pharmacokinetics*; D000959:Antihypertensive Agents / Q000493:pharmacokinetics*; D001682:Biological Availability; D002216:Captopril / Q000493:pharmacokinetics*; D005260:Female; D005790:General Adaptation Syndrome / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002216:Captopril